{"id":"W2936108326","doi":"10.1007/s10637-019-00768-6","title":"A phase 2, open-label study of brentuximab vedotin in patients with CD30-expressing solid tumors","year":2019,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Brentuximab vedotin; Medicine; CD30; Antibody-drug conjugate; Internal medicine; Adverse effect; Nausea; Mesothelioma; Oncology; Germ cell tumors; Phases of clinical research; Gastroenterology; Toxicity; Chemotherapy; Antibody; Immunology; Lymphoma; Pathology; Monoclonal antibody","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001000228,0.0001653111,0.0003894963,0.0001219524,0.00003572425,0.00003477236,0.0001363983,0.00003333597,0.00007016341],"category_scores_gemma":[0.00003952597,0.0001262805,0.00002019738,0.0002486861,0.00005505844,0.0002105075,0.00008420442,0.00007714159,0.00003950722],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001345292,"about_ca_system_score_gemma":0.0005470582,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007126246,"about_ca_topic_score_gemma":0.00002336088,"domain_scores_codex":[0.9985547,0.00004345932,0.0003899113,0.0003192994,0.000516541,0.0001760644],"domain_scores_gemma":[0.9991719,0.00007640082,0.0001957229,0.0002599363,0.000115125,0.0001809437],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0006731419,0.03168515,0.9605637,0.00003616096,0.0001119548,0.00001926054,0.002360624,0.00006482222,0.0003520541,0.0002591996,0.0006196229,0.003254323],"study_design_scores_gemma":[0.1586509,0.004531725,0.8325852,0.0007083884,0.00008537709,0.000003467205,0.0004386257,0.0003060896,0.002136666,0.000283437,0.000101649,0.00016848],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9970582,0.00003154286,9.811614e-7,0.0003752602,0.00005162275,0.001538087,0.00001628707,0.00001400547,0.0009140834],"genre_scores_gemma":[0.9979845,6.857872e-7,0.001105638,0.0003868047,0.00002979711,0.00005654614,0.0001311654,0.00001996801,0.0002849477],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1579778,"threshold_uncertainty_score":0.514957,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02765653331997186,"score_gpt":0.3151312772962788,"score_spread":0.287474743976307,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}